Bloom Burton analyst David Martin PhD has maintained their bullish stance on KHTRF stock, giving a Buy rating on May 9.
David Martin PhD has given his Buy rating due to a combination of factors that reflect Knight Therapeutics’ promising financial outlook and strategic positioning. Despite the challenges posed by foreign exchange fluctuations and hyperinflation, the company reported results that surpassed consensus expectations, indicating robust operational performance.
Furthermore, Knight Therapeutics has maintained its guidance for 2025, projecting revenues between $390 million and $405 million with a 13% EBITDA margin. This stability in guidance, coupled with the company’s ability to navigate economic headwinds, supports the positive outlook on its stock. The strategic initiatives and financial resilience demonstrated by Knight Therapeutics underpin David Martin’s confidence in recommending a Buy rating.
In another report released on May 9, RBC Capital also maintained a Buy rating on the stock with a C$8.00 price target.
